Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Free Cash Flow (2023 - 2025)

Monte Rosa Therapeutics' Free Cash Flow history spans 3 years, with the latest figure at -$47.3 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 135.63% year-over-year to -$47.3 million; the TTM value through Dec 2025 reached -$27.5 million, down 165.56%, while the annual FY2025 figure was -$27.5 million, 165.56% down from the prior year.
  • Free Cash Flow reached -$47.3 million in Q4 2025 per GLUE's latest filing, down from $103.3 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $132.7 million in Q4 2024 to a low of -$47.3 million in Q4 2025.
  • Average Free Cash Flow over 3 years is -$2.5 million, with a median of -$31.2 million recorded in 2023.
  • The largest YoY upside for Free Cash Flow was 582.73% in 2025 against a maximum downside of 135.63% in 2025.
  • A 3-year view of Free Cash Flow shows it stood at $46.7 million in 2023, then skyrocketed by 183.81% to $132.7 million in 2024, then crashed by 135.63% to -$47.3 million in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Free Cash Flow are -$47.3 million (Q4 2025), $103.3 million (Q3 2025), and -$36.4 million (Q2 2025).